

CV Isabel Devesa

Pharmacist and PhD in Pharmacology University of Valencia (2005). From 2015, Chief Scientist Officer at AntalGenis SL, a company centred in the development of novel therapies for skin diseases and related disorders. Her professional and scientific career and skills are focused on drug development in the field of neurobiology, immunology, chronic inflammation, itch and pain.

Her PhD project was develop on the pharmacological regulation of experimental arthritis and other inflammatory models, identifying the role on novel potential therapies and molecular targets. Her scientific experience and knowledge in immunology was expanded and developed at Experimental Rheumatology and Advanced Therapeutics Laboratory, University Medical Centre Nijmegen, The Netherlands (MEC-Fullbright fellow 2006-2007, 2002-2004). In this research centre, she studied the mechanism involved in cartilage degradation, bone erosion, and the role on the novel Th17 cells on the development of arthritis. As Marie-Curie postdoctoral researcher (2005-2006) at the preclinical Research Department of Bioxell SpA, (Italy), she contributed to the development of new therapies to treat psoriasis and arthritic pain. As senior researcher at preclinical research department at Newron Pharmaceuticals SpA, Italy (2007-2009), her research line was centred in the preclinical development of novel molecules to treat chronic painful diseases. Finally, she specialized in sensory neurobiology at Institute of Molecular and Cellular Biology, Universidad Miguel Hernández de Elche (2009-2015). At the Laboratory of Sensory neurobiology, her projects was the understanding of the molecular mechanism involved in the inflammatory sensitization processes; being neuronal exocytosis and TRP channels the target processes. The final goal was the discovery novel molecules as potential novel analgesics.

Dr. Devesa scientific achievements are demonstrated by more than 20 articles in international recognized journal in the field, more than 25 international congresses communications, 4 patents, and public concurred-financed projects. Finally, at AntalGenics, venture capital investment and together with several public funding achievement will support a new drug develop a novel treatment for psoriasis pruritus and cosmeceuticals for sensitive skin care. Expert in vivo preclinical efficacy testing, drug screening, and drug

development, contributes and leads to the successful R&D program at AntaGenics formed by a team of 11 scientists.